Engitix company

Engitix is using its proprietary human organ decellularisation technology to develop tissue engineered products for application in regenerative medicine and drug-target research. Engitix’ core expertise is treatment and research of liver disease using its proprietary technologies for human extra-cellular matrix (ECM) scaffolds and 3D spheroids for bioartificial liver devices. The scaffold technology is applicable to other organs and disease aetiologies including pancreatic and intestine scaffold products.
Technology: Regenerative Medicine
Industry: Personalized Medicine
Headquarters: London, England, United Kingdom
Founded Date: 2016
Employees Number: Undisclosed
Funding Status: Early Stage Venture
Total Funding: £5M
Last Funding Type: Series A

Visit Website
Register and Claim Ownership